Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | APEX1 | P27695 | 1/20 | 0.45 |
| ▸ | NQO1 | P15559 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TPMT | P51580 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | GABRP | O00591 | 1/20 | 0.35 |
| ▸ | GABRD | O14764 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9590560 | 0.81 | KMT2A (0.39) | KMT2AMEN1NQO1KDM4EGLA | |
| SCHEMBL6942194 | 0.81 | KMT2A (0.59) | KMT2AMEN1APEX1MCL1GPR35 | |
| SCHEMBL2866022 | 0.79 | MAPT (0.42) | KMT2AMEN1APEX1GPR35KDM4E | |
| SCHEMBL21313108 | 0.79 | GPR35 (0.48) | KMT2AMEN1NQO1MCL1GPR35 | |
| SCHEMBL15349677 | 0.79 | KMT2A (0.57) | KMT2AMEN1APEX1MCL1GPR35 | |
| SCHEMBL8587349 | 0.79 | POLB (0.39) | KMT2AMEN1NQO1KDM4EGLA | |
| SCHEMBL28443819 | 0.79 | KMT2A (0.57) | KMT2AMEN1APEX1MCL1GPR35 | |
| SCHEMBL4367459 | 0.77 | KMT2A (0.55) | KMT2AMEN1APEX1MCL1GPR35 | |
| SCHEMBL9310899 | 0.77 | KMT2A (0.55) | KMT2AMEN1APEX1MCL1GPR35 | |
| SCHEMBL12559174 | 0.77 | KMT2A (0.41) | KMT2AMEN1APEX1NQO1MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200139163-A1 | Compositions For Removing Surface Coatings | PALMER JAKE (US) | 2020-05-07 | — | — | US | claimed |
| EP-4326702-A1 | METHODS FOR SYNTHESIS OF AN ADVANTAGEOUS N-HETEROCYCLIC CARBENE CATALYST | XF Technologies Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| US-20240059701-A1 | Methods for Synthesis of an Advantageous N-Heterocyclic Carbene Catalyst | XF BIOSOLUTIONS, LLC | 2024-02-22 | — | — | US | disclosed |
| CN-117529466-A | Method for synthesizing favorable N-heterocyclic carbene catalyst | 埃克斯福科技公司 | 2024-02-06 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| WO-2022225825-A1 | METHODS FOR SYNTHESIS OF AN ADVANTAGEOUS N-HETEROCYCLIC CARBENE CATALYST | XF TECHNOLOGIES INC. (US) | 2022-10-27 | — | — | WO | disclosed |
| US-20220017524-A1 | ARYL HYDROCARBON RECEPTOR (AHR) ACTIVATOR COMPOUNDS AS CANCER THERAPEUTICS | THE BROAD INSTITUTE, INC. (US) | 2022-01-20 | — | — | US | disclosed |
| CN-111655372-A | Catalysts containing furans and use thereof in hydrotreating and/or hydrocracking processes | IFP 新能源公司 | 2020-09-11 | — | — | CN | disclosed |
| US-5849693-A | Cyclic compounds linked by a heterocyclic ring useful as inhibitors of platelet glycoprotein IIb/IIIa | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-12-15 | — | — | US | disclosed |
| US-5773411-A | CARDIOVASCULAR DISORDERS AND BRAIN DISORDERS AND COAGULANTS | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-06-30 | — | — | US | disclosed |
| US-5691329-A | Compounds containing basic and acidic termini useful as fibrinogen receptor antagonists | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-11-25 | — | — | US | disclosed |
| US-5563158-A | CARDIOVASCULAR DISORDERS | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-10-08 | — | — | US | disclosed |
| EP-0672059-A1 | CYCLIC COMPOUNDS LINKED BY A HETEROCYCLIC RING USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-09-20 | — | — | EP | disclosed |
| WO-1995018111-A1 | COMPOUNDS CONTAINING BASIC AND ACIDIC TERMINI USEFUL AS FIBRINOGEN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-07-06 | — | — | WO | disclosed |
| WO-1994011398-A1 | CYCLIC COMPOUNDS LINKED BY A HETEROCYCLIC RING USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017524-A1 | ARYL HYDROCARBON RECEPTOR (AHR) ACTIVATOR COMPOUNDS AS CANCER THERAPEUTICS | AHR, ESRRA, AR | KMT2A 1057/4885MEN1 1705/4885APEX1 1663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.